A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Clinical Trial

Official title:

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Regeneron Anti-SARS-CoV-2 Monoclonal Antibody (a COVID-19 Therapeutic) in Adult Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05505448
• Other study ID #: R14284-HV-2253
• Secondary ID: 2022-002181-33
• Status: Completed
• Phase: Phase 1
• Start date: September 15, 2022
• Est. completion date: May 30, 2023

Study information

• Verified date: July 2023
• Source: Regeneron Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the safety and tolerability of REGN14284 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (SAEs).

The secondary objectives of the study are:

• To assess the concentration-time profile of REGN14284 in serum

• To assess the immunogenicity of REGN14284

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Key Inclusion Criteria:

1. Has SARS-CoV-2-negative test result from a sample collected =72 hours prior to randomization as described in the protocol.

2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening

3. Has a body mass index (BMI) between 18 and 31 kg/m2 (inclusive) at the screening visit

4. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, laboratory safety testing and ECGs performed at screening and/or prior to administration of study drug

Key Exclusion Criteria:

1. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, infectious, autoimmune, oncologic, psychiatric or neurological disease, as assessed by the investigator as described in the protocol

2. Presents any concern to the investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study

3. Was hospitalized (ie, >24 hours) for any reason within 30 days of the screening visit

4. Has a history of alcohol or drug abuse as determined by the investigator

5. Has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction to drugs or food as described in the protocol

6. Use of any medications or nutritional supplements within approximately 5 half-lives or 2 weeks, whichever is longer, prior to first administration of the study drug through the end of the study, except for the permitted medications listed as described in the protocol

7. Participated in any clinical research study evaluating another investigational drug including biologics or specific immunotherapy, within at least 5 half-lives or 90 days (whichever is longer) of an investigational biologic drug, or at least 4 weeks for small molecules or other investigational drugs, prior to the screening visit

NOTE: Other protocol defined inclusion / exclusion criteria apply

Related Conditions & MeSH terms

• COVID-19
• Healthy

Intervention

Drug:
• REGN14284
Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol
• Matching Placebo
Single ascending IV or SC administration per the protocol

Locations

Country	Name	City	State
Belgium	Universitair Ziekenhuis Leuven Gasthuisberg Campus	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
Regeneron Pharmaceuticals

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence and severity of all treatment emergent adverse events (TEAEs)		Through approximately day 169
Primary	Occurrence and severity of all severe adverse events (SAEs)		Through approximately day 169
Secondary	Concentrations of REGN14284 in serum over time		Through approximately day 169
Secondary	Incidence of Anti-drug antibodies (ADAs) to REGN14284 over time		Through approximately day 90
Secondary	Titer of ADAs to REGN14284 over time		Through approximately day 90